[HTML][HTML] Polymorphonuclear myeloid-derived suppressor cells limit antigen cross-presentation by dendritic cells in cancer

A Ugolini, VA Tyurin, YY Tyurina, EN Tcyganov… - JCI insight, 2020 - ncbi.nlm.nih.gov
A Ugolini, VA Tyurin, YY Tyurina, EN Tcyganov, L Donthireddy, VE Kagan, DI Gabrilovich
JCI insight, 2020ncbi.nlm.nih.gov
DCs are a critical component of immune responses in cancer primarily due to their ability to
cross-present tumor-associated antigens. Cross-presentation by DCs in cancer is impaired,
which may represent one of the obstacles for the success of cancer immunotherapies. Here,
we report that polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC) blocked
cross-presentation by DCs without affecting direct presentation of antigens by these cells.
This effect did not require direct cell-cell contact and was associated with transfer of lipids …
Abstract
DCs are a critical component of immune responses in cancer primarily due to their ability to cross-present tumor-associated antigens. Cross-presentation by DCs in cancer is impaired, which may represent one of the obstacles for the success of cancer immunotherapies. Here, we report that polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC) blocked cross-presentation by DCs without affecting direct presentation of antigens by these cells. This effect did not require direct cell-cell contact and was associated with transfer of lipids. Neutrophils (PMN) and PMN-MDSC transferred lipid to DCs equally well; however, PMN did not affect DC cross-presentation. PMN-MDSC generate oxidatively truncated lipids previously shown to be involved in impaired cross-presentation by DCs. Accumulation of oxidized lipids in PMN-MDSC was dependent on myeloperoxidase (MPO). MPO-deficient PMN-MDSC did not affect cross-presentation by DCs. Cross-presentation of tumor-associated antigens in vivo by DCs was improved in MDSC-depleted or tumor-bearing MPO-KO mice. Pharmacological inhibition of MPO in combination with checkpoint blockade reduced tumor progression in different tumor models. These data suggest MPO-driven lipid peroxidation in PMN-MDSC as a possible non–cell autonomous mechanism of inhibition of antigen cross-presentation by DCs and propose MPO as potential therapeutic target to enhance the efficacy of current immunotherapies for patients with cancer.
ncbi.nlm.nih.gov